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Abstract
Background and Aims: GLI1, as an indispensable transcriptional factor of Hedgehog signaling pathway, plays an important
role in the development of pancreatic cancer (PC). DNA methyltransferases (DNMTs) mediate the methylation of quantity of
tumor-related genes. Our study aimed to explore the relationship between GLI1 and DNMTs.
Methods: Expressions of GLI1 and DNMTs were detected in tumor and adjacent normal tissues of PC patients by
immunohistochemistry (IHC). PANC-1 cells were treated by cyclopamine and GLI1-siRNA, while BxPC-3 cells were transfected
with overexpression-GLI1 lentiviral vector. Then GLI1 and DNMTs expression were analyzed by qRT-PCR and western blot
(WB). Then we took chromatin immunoprecipitation (ChIP) to demonstrate GLI1 bind to DNMT1. Finally, nested MSP was
taken to valuate the methylation levels of APC and hMLH1, when GLI1 expression altered.
Results: IHC result suggested the expressions of GLI1, DNMT1 and DNMT3a in PC tissues were all higher than those in
adjacent normal tissues (p,0.05). After GLI1 expression repressed by cyclopamine in mRNA and protein level (down-
regulation 88.162.2%, 86.462.2%, respectively), DNMT1 and DNMT3a mRNA and protein level decreased by 91.6%62.2%
and 83.864.8%, 87.462.7% and 84.461.3%, respectively. When further knocked down the expression of GLI1 by siRNA
(mRNA decreased by 88.662.1%, protein decreased by 63.564.5%), DNMT1 and DNMT3a mRNA decreased by 80.962.3%
and 78.663.8% and protein decreased by 64.862.8% and 67.565.6%, respectively. Over-expression of GLI1 by GLI1 gene
transfection (mRNA increased by 655.5685.9%, and protein increased by 272.3614.4%.), DNMT1 and DNMT3a mRNA and
protein increased by 293.0614.8% and 578.3658.5%, 143.5617.4% and 214.0618.9%, respectively. ChIP assays showed
GLI1 protein bound to DNMT1 but not to DNMT3a. Results of nested MSP demonstrated GLI1 expression affected the DNA
methylation level of APC but not hMLH1 in PC.
Conclusion: DNMT1 and DNMT3a are regulated by GLI1 in PC, and DNMT1 is its direct target gene.
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Introduction
Pancreatic cancer is a highly lethal disease, which is usually
diagnosed in an advanced state for which there are little or no
effective therapies. It has the worst prognosis of any major
malignancy (3% 5-year survival) and is the fourth most com-
mon cause of cancer death yearly in multiple countries. Despite
advances in surgical and medical therapy, little effect has been
made on the mortality rate of this disease. One of the major
hallmarks of pancreatic cancer is its extensive local tumor invasion
and early systemic dissemination. So, it is an urgent need to reveal
the underlying mechanisms by which pancreatic cancer cells
become invasive and metastatic.
Hedgehog signaling cascade is aberrantly activated in a variety
of human tumors including pancreatic cancer (PC) [1]. The
activation of Hh pathway requires the binding of Hh ligands, such
as Shh, Ihh and Dhh, to Hh receptor Patched (Ptch), thus
releasing Hh signaling molecule Smoothened (Smo) from Ptch-
induced inhibition. Smo in turn initiates the release of the
transcription factor GLI from the cytoskeleton by a complex of
proteins, thus facilitates its nuclear translocation, GLI activators
then bind to the GACCACCCA-like motif for the transcriptional
regulation of Hedgehog target genes, which are involved in the
regulation of cellular proliferation, cell-fate determination, cellular
survival, and epithelial-to mesenchymal transition(EMT) and etc.
A membrane glycoprotein Human Hedgehog Interacting Protein
(HHIP) can bind to all three Hh ligands and functions to
negatively regulate the activity of Hh signaling pathway [2,3].
DNA methylation change is a key contributor to human
oncogenesis [4]. In human cancer cells, the normal somatic pattern
of DNA methylation is altered. These changes include increased
CpG island methylation, which mediates tumor suppressor gene
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to genomic instability [5,6]. Cytosine DNA methylation is cata-
lyzed and regulated by a small family of DNA methyltrans-
ferases (DNMTs), including DNMT1, DNMT3a, DNMT3b and
DNMT3L[7].Although cancer-specificmutations ofDNMTs have
not been reported, several studies suggest that DNMT genes are
overexpressed in human cancer and during cellular transformation
[8–11]. Several mechanisms seem to account for DNMTs over-
expression, including aberrant cell cycle control, increased mRNA
and protein stability, and E2F-mediated DNMTs promoter
activation [11–14].
Although the evidences above indicate that DNMTs and active
Hh signaling pathway are both involved in the development of
pancreatic cancer, little is known about the correlation between
DNMTs and members of the Hh pathway. Here, this study was
undertaken to investigate the expression of GLI1 and DNMTs,
and the correlation between them in human pancreatic cancer.
Materials and Methods
Ethics statement
Tissues of pancreatic cancer and corresponding non-cancerous
pancreas were obtained from Shanghai Tenth People’s Hospital,
where we have obtained ethics approval from Medicine and Life
Sciences Ethics Committee.
Cell cultures and drug treatment
Human pancreatic cancer cell line PANC-1 and BxPC-3 were
grown in RPMI-1640 supplemented with 10% fetal bovine serum
(FBS),streptomycin100 mg/ml,and penicillin100 U/mlat37uCin
5% CO2 and 95% air-humidified incubator. BxPC-3 cells were
cultured for lentiviral transfection of overexpression-GLI1 lentiviral
vector. PANC-1 cells were plated at a density of 4610
4 cells/cm
2 in
a six-well plate, Cyclopamine (Sigma, St. Louis, MO) was dissolved
in 100% ethanol and then diluted fresh on the day of testing for cell
Table 1. Oligonuleotides used for qRT-PCR.
Gene Accession No. Tm(6C) Size (bp) Sequence (5’ to 3’)
GLI1 NM_001160045.1 59 491 F - CCAACTCCACAGGCATAC
R - CTTACATACATACGGCTTCTC
DNMT1 NM_001130823.1 60 132 F - CCATCAGGCATTCTACCA
R - CGTTCTCCTTGTCTTCTCT
DNMT3a NM_022552.3 60 111 F - TATTGATGAGCGCACAAGAGAGC
R - GGGTGTTCCAGGGTAACATTGAG
doi:10.1371/journal.pone.0027684.t001
Table 2. Oligonucleotides used for XChIP-PCR.
Gene Site Primer Tm(6C) Size (bp) Sequence (5’ to 3’)
DNMT1 1 DNMT1-A 53 317 F - GCTGAGGCATGAGAATCGCTTGAA
R - GGAGGATCGCTTGAGGTTAGGAGTT
2 DNMT1-B 54 243 F - AGGCTGGAATGTAGTGGTACAATCA
R - AGGGTGGGAGGATCGCTTGA
2 and 3 DNMT1-C 54 214 F - GTGATCTTCCTGCCTCAACCTCTG
R - CGCCTGTCATCCCAGCACTTT
4 DNMT1-D 55 123 F - CCAAAGTGCTGGGATGACAGG
R - GCTAGTACCAAGAATCTCACAGTGTA
5 DNMT1-E 53 400 F - GAGGTTGGATTGGAACTGAGGACTT
R - CATCTCGGAGGCTTCAGCAGAC
DNMT3a 1 DNMT3a-A 54 332 F - AGGCTGGAATGTAGTGGTACAATCA
R - AGGGTGGGAGGATCGCTTGA
2 and 3 DNMT3a-B 55 124 F - CCACCACCAACTCCAGCAATC
R - CTACTCAGCACTTCAGCTATATCACA
4 DNMT3a-C 55 194 F - GCCATGTCCTGTGCCAGTCA
R - CTCACTATGTGCTCATCTCACTCCT
5 DNMT3a-D 57 182 F - TGAGTGGCTGTGCTGGTGGAA
R - TGAGGTGGGAGGTTGAATGAAATGAC
6 DNMT3a-E 54 100 F - ATCTTTCAGTCTTCCAGTGCCCAAC
R - TCTCTGAGATGAGCTGCCTTGAAG
Supplementary figure legends.
doi:10.1371/journal.pone.0027684.t002
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concentration of Cyclopamine at 10 mM for 24 hours.
Immunohistochemistry (IHC)
Twenty pairs of PC and corresponding non-cancerous pancreas
tissues were obtained from Shanghai Tenth People’s Hospital.
Pancreatic patients’ tumor sections were de-paraffinised, rehydrat-
ed, treated with 10 mM citrate buffer at 95uC to retrieve antigens,
blocked with 5% BSA, and incubated with mouse anti-GLI1
(1:100), rabbit anti-DNMT1 (1:100) or rabbit anti-DNMT3a
antibody (1:100; all from Santa Cruz Biotech) overnight. The tissue
sections were then incubated with secondary antibodies and
DAB reagent (Gene Tech, Shanghai, China). The sections were
then counterstained with hematoxylin, then were dehydrated and
visualized with 3.3-diaminobenzidine(Gene Tech, Shanghai, Chi-
na). Negative controls were performed in each case by replacing the
primary antibody with PBS.
RT-PCR and quantitative real-time PCR (qRT-PCR)
Total RNA was extracted from PANC-1 cells using Trizol
reagent (Invitrogen, California, USA), 1 mg RNA was reverse-
transcribed to cDNA using PrimeScript RT reagent Kit (Takara
Bio, Shiga, Japan). To determine the quantity of mRNA, the
cDNA was amplified by real-time PCR with SYBR Premix Ex
Taq RT-PCR kit (Takara Bio, Shiga, Japan), and the housekeep-
ing gene b-actin was used as the internal control. The SYBR
Green assays were performed in triplicate on a 7900HT real-time
instrument (Applied Biosystems, CA, USA). Primers used for
qRT-PCR were listed (Table 1). The relative expression levels
were calculated using the 2
2DDCT method.
Western Blot (WB)
Total cell lysate was prepared in a 16 sodium dodecyl sulfate
buffer. Proteins in the same amount were separated by 6% SDS-
PAGE and transferred onto polyvinylidene fluoride (PVDF)
membranes. After incubation with antibodies specific for DNMT1
(Santa Cruz Biotechnology, Santa Cruz, CA) or DNMT3a (Santa
Cruz Biotechnology, Santa Cruz, CA) or GLI1 (Santa Cruz
Biotechnology, Santa Cruz, CA) or b-actin (Cell Signaling Technol-
ogy, Danvers, MA), the blots were incubated with goat anti-rabbit or
anti-mouse secondary antibody (Santa Cruz Biotechnology, Santa
Cruz, CA) and visualized with enhanced chemiluminescence.
Small interfering RNA mediated inhibition of GLI1
expression
Stealthsmallinterference RNA(siRNA) sequencesforGLI1were
designed and synthesized by GenePharma to target GLI1 mRNA.
The coding strand for GLI1 siRNA was 5’-GGCTCAGCTTGTG-
TGTAAT-3’. An unrelated siRNA sequence was used as a control.
In this experiment, cells were incubated for 12 h and transfected at
approximately 60% confluency with 50 nm siRNA duplexes using
Lipofectamine
TM2000 (Invitrogen, Carlsbad, CA) according to the
manufacturer’s instructions. All the experiments were performed
72 hours after transfection.
Lentiviral Transfection of Overexpression-GLI1 Lentiviral
Vector
Lentiviral transfection of overexpression-GLI1 lentiviral vector
pGC-FU-GLI1 were performed as we reported previously [15].
Human GLI1 cDNA was purchased from Open-Biosystem (USA).
The complete cDNA sequence of GLI1 was generated by PCR,
and inserted into pGC-FU-3FLAG Vector (GeneChem Company,
Shanghai, China) which was linearized with Age I and Nhe I
(Fig. S1, S2). The resultant 3320-bp fragment was confirmed
by sequencing (Fig. S3). Lentiviral vector were produced by
co-transfected into 293T cells with helper construct. Titers of 2–
5610
7 TU/ml were routinely achieved. BxPC-3 cells were
transfected with the lentiviral vector and GLI1 expression was
established by real-time PCR and western blot analysis.
Chromatin Immunoprecipitation (ChIP)
DNA-GLI1-protein immune complexes were preparated as we
reported previously [15], after reverse cross-linked, DNA was
extracted with phenol/chloroform and precipitated. The presence
of the DNMT1 and DNMT3a promoter domain containing GLI1
motifs in immunoprecipitated DNA was identified by PCR using
primers (table 2). The PCR conditions for the DNMT1 and
DNMT3a promoter region were: denaturation 30 seconds at
94uC, annealing 30 s, elongation 1 minute at 72uC. Annealing
temperatures were listed in table 2. The amplification of the
DNMT1 and DNMT3a promoter region was analyzed after 40
cycles. All experiments were repeated at least three times.
DNA preparation
DNA were extracted by TIANamp Genomic DNA Kit
(Tiangen, Beijing, China). Approximately 500 ng extracted DNA
were bisulfite conversed and column-purified by EZ DNA
Methylation-Gold
TM Kit (Zymo Research, Orange, CA , USA)
to make 10 ml sample.
Figure 1. GLI1, DNMT1 and DNMT3a protein expression in PC
tissues and adjacent normal tissues. Immunohistochemical exam-
ination for GLI1, DNMT1, DNMT3a protein were performed in 20 pairs of
PC and adjacent normal tissues. Representative pictures are shown.
Adjacent normal tissues exhibited no or faint staining for GLI1, DNMT1
and DNMT3a, however, the incidence of all the three proteins nuclear
immunoreactivity was much higher in PC tissues. All photomicrographs
were obtained at 6200 magnification.
doi:10.1371/journal.pone.0027684.g001
DNMT1 and DNMT3a Are Regulated by GLI1
PLoS ONE | www.plosone.org 3 November 2011 | Volume 6 | Issue 11 | e27684Nested MSP
DNA methylation status on the promoter regions of the APC
(adenomatous polyposis coli) and hMLH1 (human mutl homolog
1) were determined by the method of MSP further modified as a
nested two-step approach with the primers described previously
[16,17]. In the step one of the nested MSP, primers were designed
to amplify both methylated and unmethylated genomic regions.
Products were equally diluted 1:100 and subjected to the step
two of the nested MSP with primers designed to recognize
bisulfite-induced sequence differences between methylated and
unmethylated genomic regions. The PCR conditions for step one
were as follows: 95uC hot start65 min, then 40 repetitive cycles of
denaturation (95uC630 s), annealing (56uC630 s), extension
(72uC630 s) followed by a final 5 min extension at 72uC. And
that for Step two were: 95uC hot start65 min, then 30 repetitive
cycles of denaturation (95uC630 s), annealing (59uC630 s for
APC, 60uC630 s for hMLH1), extension (72uC630 s) followed by
a final 5 min extension at 72uC. MSP products were separated
electrophoretically on 2% agarose gels.
Statistical Analysis
Quantitative data are expressed as the mean 6 standard
deviation (SD). Real-time PCR data was analyzed according to the
differences of target gene expression by the paired t-test and were
2
2DDCT transformed before analysis. IHC data was analyzed using
the Chi-squared test. A p-value of less than 0.05 was considered
statistically significant.
Results
GLI1, DNMT1 and DNMT3a were up-regulated in human
pancreatic cancer tissues
To confirm the roles of GLI1 and DNMTs in the development
of human pancreatic cancer, we first examined whether their
expressions were altered in cancer tissues. Therefore, we studied
GLI1, DNMT1 and DNMT3a expression in 20 paired biopsy
tissues of PC patients by IHC. We found that GLI1, DNMT1 and
DNMT3a expression were all higher in most PC compared with
normal tissues (14/20 versus 5/20, p=0.004; 15/20 versus 6/20,
p=0.004; 13/20 versus 5/20, p=0.011; respectively; Figure 1).
14 of 20 PC cases had higher expression of GLI1 protein, among
which 12 cases expressed higher levels of DNMT1 protein
(p=0.004) and 11 cases expressed higher levels of DNMT3a
protein (p=0.012).
Cyclopamine and GLI1 siRNA both inhibited DNMT1 and
DNMT3a expression
To determine whether Hh activity affected the expression of
DNMTs, we used cyclopamine, a classical inhibitor of Hh
signaling pathway, to decrease the expression of GLI1. PANC-
1 cells, which were previously reported to express a high level of
GLI1 [15],were treated with 10 mMc y c l o p a m i n ef o r2 4 h .
Afterward, qRT-PCR and WB were taken to analyze the
expression of GLI1 and DNMTs. DNMT1 and DNMT3a
mRNA decreased by 91.6.062.2% and 83.864.8%, respec-
t i v e l y ,w h e nG L I 1m R N Ad e c r e a s e db y8 8 . 1 62.2%. DNMT1
and DNMT3a protein decreased by 87.462.7% and
84.461.3% when GLI1 protein decreased by 86.462.2%
(Figure 2).
We further designed and synthesized GLI1 siRNA, then
transfected into PANC-1 cell line. PANC-1 cells transfected
with an unrelated siRNA sequence was used as a negative
control [18], and PANC-1 those treated with Lipofectami-
ne
TM2000 (Invitrogen, Carlsbad, CA) only was used as blank
control. 72 hours after transfection, qRT-PCR and WB were
taken to determine the expression of GLI1 and DNMTs.
DNMT1 and DNMT3a mRNA decreased by 80.962.3%
Figure 2. GLI1, DNMT1 and DNMT3a were inhibited in PANC-1 cell line after which treated by Cyclopamine. PANC-1 cells were treated
with 10 mM cyclopamine for 24 hours, then relative expression of GLI1, DNMT1 and DNMT3a mRNA was assessed by qRT-PCR (A, B, C), while the
expression of GLI1, DNMT1 and DNMT3a protein was analyzed by Western blot (D). The inset shows a substantial decrease in GLI1, DNMT1 and
DNMT3a expression. The results were normalized to that of b-actin expression. All data were presented as the mean 6 SD of three independent
experiments.
doi:10.1371/journal.pone.0027684.g002
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by 88.662.1%. DNMT1 and DNMT3a protein decreased by
64.862.8% and 67.565.6% when GLI1 protein decreased
by 63.564.5% (Figure 3).
The expression of DNMT1 and DNMT3a were
upregulated with GLI1 overexpression
To further confirm the regulation of DNMT1 and DNMT3a by
GLI1, we designed and constructed a lentivirus vector that
Figure 3. DNMT1 and DNMT3a were suppressed after transfected by GLI1-siRNA in PANC-1 cells. PANC-1 cells were transfected with
GLI1 siRNA, 72 hours after transfection, relative expression of GLI1, DNMT1 and DNMT3a mRNA was assessed by qRT-PCR (A, B, C), while the
expression of GLI1, DNMT1 and DNMT3a protein was analyzed by Western blot (D). The inset shows a substantial decrease in DNMT1 and DNMT3a
expression after GLI1 interference. The results were normalized to that of b-actin expression. All data were presented as the mean 6 SD of three
independent experiments.
doi:10.1371/journal.pone.0027684.g003
Figure 4. DNMT1 and DNMT3a were up-regulated after GLI1 over-expression. BxPC-3 cells were transfected with pGC-FU-GLI1, relative
expression of GLI1, DNMT1 and DNMT3a mRNA was assessed by qRT-PCR (A, B, C), while the expression of GLI1, DNMT1 and DNMT3a protein was
analyzed by Western blot (D). The inset showed a substantial increase in DNMT1 and DNMT3a expression after GLI1 over-expression. The results were
normalized to that of b-actin expression. All data were presented as the mean 6 SD of three independent experiments.
doi:10.1371/journal.pone.0027684.g004
DNMT1 and DNMT3a Are Regulated by GLI1
PLoS ONE | www.plosone.org 5 November 2011 | Volume 6 | Issue 11 | e27684overexpressed GLI1, and transfected it into BxPC-3 with the
lowest GLI1 expression in PC cell lines as we previous reported
[15]. Cells transfected with empty lentivirus vector were used as
negative controls, while cells without transfection were used as
blank controls. 48 hours after transfection, qRT-PCR and WB
were taken to determine the expression of GLI1 and DNMTs in
the three cell lines. DNMT1 and DNMT3a mRNA increased
by 293.0614.8% and 578.3658.5%, respectively, when GLI1
mRNA increased by 655.5685.9%. DNMT1 and DNMT3a
protein increased by 143.5617.4% and 214.0618.9%, res-
pectively, when GLI1 protein increased by 272.3614.4%
(Figure 4).
Figure 5. Potential GLI1 binding sites on the DNMT1’s and DNMT3a’s promoter. Two parallel lines on top of the figure represented DNMT1
or DNMT3a DNA, respectively(A, B), within which gray frames represented exons, white frames represented introns, and black frames represented
promoter. In the promoter, small gray frames marked with number 1 to 5 (A) or 1 to 6 (B) represented the potential GLI1 binding sites, which has only
two nucleotides difference (underlined) from GLI1 consensus binding sequence, GACCACCCA. Primers were designed to amplify the DNMT1 (A) or
DNMT3a (B) promoter region containing the putative GLI1-binding site. The position and length of products amplificated by each primer were shown.
doi:10.1371/journal.pone.0027684.g005
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of DNMT1 gene
We have, so far, proved the role of GLI1 in DNMT1 and
DNMT3 expression. However, the mechanism underlying such
regulation remains to be elucidated. To explore whether DNMTs
are directly regulated by GLI1 or not, we searched the DNMT1 and
DNMT3a promoter for potential GLI1 binding sites to the DNA
consensus sequence 5’-GACCACCCA-3’ [19] or 5’-TGGGTGGT-
C-3’ [20], and five high-scoring candidate sites of GLI1 targets were
found in DNMT1’s promoter and six in DNMT3a’s. Each site has
onlytwo nucleotide’sdifferenceincomparewith 5’-GACCACCCA-
3’ or 5’-TGGGTGGTC-3’ (Figure 5). ChIP was taken to confirm
the bounding relationship between GLI protein and DNMT1/3a
gene. DNA extracted from PANC-1 cells were sonicated into 100–
1000 bp (Fig. S4) and as the ChIP-PCR template. The result of
DNA electrophoresis showed the predicted DNA band in INPUT,
GLI1-Ab,andpostivecontrol groups using humanDNMT1primer-
C, and not in the IgG and negative control groups (Figure 6). Only
INPUT and the positive control showed the predicted band using
human DNMT1 primer-A, C-E and DNMT3a primer A-E but not
in GLI-Ab, IgG, and negative groups (data not shown). As positive
product amplified by DNMT1 primer-C contains candidate GLI1
binding site 2 and 3 (Table 2 and Figure 5), while product amplified
by DNMT1 primer-B contains candidate GLI1 binding site 2 was
negative, and results of sequence analysis showed that the sequences
were the same as that of the DNMT1 gene promoter of site 3 (Fig.
S5), suggested that GLI1 was bound to the DNMT1 gene promoter
of site 3 (GGCCTCCCA).
The DNA methylation levels of APC but not hMLH1
promoter regions changed with GLI1 expression
Amount of tumor-related genes were found to be silenced by
DNA methylation in PC, including APC (adenomatous polyposis
coli) and hMLH1 (human mutl homolog 1). To access whether
inhibiting or increasing the expression of GLI1 could also lead to
hypo- or hyper-methylation of APC and hMLH1 in PC, we used
nested MSP to evaluate the methylation status of PANC-1 with or
without GLI1 knockdown and BxPC-3 with or without GLI1
over-expression, respectively. Results showed that APC DNA
methylation level increased in BxPC-3 cells transfected with
Overexpression-GLI1 Lentiviral Vector in comparison with the
negative control, and was inhibited in PANC-1 cells transfected
with GLI1-siRNA in comparison with the negative control.
However, the DNA methylation level of hMLH1 promoter region
was not significantly changed after transfection (Figure 7). This
probably because DNA methylation is coordinated by a family of
DNMTs comprising DNMT1, -3a, -3b and -3L, maybe the
expression change of only DNMT1 and -3a regulated by GLI1
was not sufficient to affect the DNA methylation levels of every
tumor-related genes [21].
Discussion
In this study, we found that GLI1, DNMT1 and DNMT3a are
over-expressed in PC tissues compared with the corresponding non-
cancerous pancreas tissues, then we showed that DNMT1 and
DNMT3a expression changed according to the GLI1 expression in
PANC-1 and BxPC-3 cell lines by specific GLI1 interference and
gene transfection, as well as pharmacological method in vivo.M o r e
importantly, we proved beyond a reasonable doubt that GLI1 was
abletobindtotheDNMT1genepromoterofsite3(GGCCTCCCA)
by the ChIP experiments. Finally, we used nested MSP to
demonstrate that GLI1 expression affected the DNA methylation
level of APC but not hMLH1 in PC. To the best of our knowledge,
this is the first report demonstrated GLI1 as a transcriptional
factor that regulated DNMT1 and -3a expression as well as APC
methylation level in PC, and DNMT1 is its direct target gene.
GLI1, as a transcriptional factor of Hh signaling pathway, is
upregulated in most digestive tumors including PC [22,23]. Thus
far, only a few downstream targets of GLI1 have been identified
[24]. Recently, it was reported to be involved in PC invasion and
metastasis, and has become a new target for treatment [25,26].
However, little was known about the actual mechanism implied in
its promotion of invasion and metastasis in PC. Moreover, we
focused on accumulating evidence which demonstrated that
carcinoma in various organs, including pancreas, is associated
with aberrant DNA methylation, in which DNMTs is the key
catalyst significantly correlated with accumulation of methylation
of tumor-related genes, among which some were associated
withcell proliferation such as APC, some were related with the
reparation of DNA damage such as hMLH1, some were invasion-
or metastasis-related, such as TIMP-3, SPARK, and CDH1, or
cell death-related such as DAPK-1, thus playing an important role
in multistage carcinogenesis of the pancreas from early precan-
cerous stages to malignant progression [27]. Recently, it was found
that tumor burden is significantly reduced with decreasing
DNMT1 levels in vivo, suggesting that DNMTs mediated DNA
methylation is involved in pancreatic carcinogenesis [28]. Based
on this study and previous reports above, it’s possible that GLI1-
DNMTs cascade help to invasion or metastasis through promoting
the methylation of some invasion- or metastasis-related genes, and
Figure 6. Identification of GLI1 binding to DNMT1 promoter by
Chromatin Immunoprecipitation (ChIP). Lysates from PANC-1 cells
were subjected to Chromatin immunoprecipitation by anti-GLI1
antibody. Sonicated chromatin was used as INPUT DNA control (INPUT).
RNA polymerase II was used as positive control (PC). IgG was used as
random control (IgG) and b-actin Ab was used as negative control (NC).
The band of ChIP-PCR products amplified by DNMT1 Primer-C (i) and by
DNMT1 Primer-B (ii) were shown.
doi:10.1371/journal.pone.0027684.g006
Figure 7. Up- or under-expression of GLI1 affected DNA
methylation levels of APC but not hMLH1. Results of nested
MSP of APC and hMLH1 in six kinds of PC cells respectively were shown.
B represented BxPC-3 cells; B-G+ represented BxPC-3 transfected with
pGC-FU-GLI1 to make GLI1 over-expression, and B-NC represented its
negative control; P represented PANC-1; P-G-si represented PANC-1
transfected with GLI1-siRNA and P-NC represented its negative control.
Positive bands under M and U represented the methylated and
unmethylated DNA of the corresponding genes in the right panel,
respectively.
doi:10.1371/journal.pone.0027684.g007
DNMT1 and DNMT3a Are Regulated by GLI1
PLoS ONE | www.plosone.org 7 November 2011 | Volume 6 | Issue 11 | e27684may facilitate tumor growth by promoting the methylation of some
cell death-related genes.
Our study showed that DNMT3a expression is regulated by
GLI1 in human pancreatic cancer. However, the actual mechanism
in the regulation of DNMT3a by GLI1 is still unknown. Recent
years, many manuscripts have been reported that some microRNA
families could target DNMTs in a diversity of human cancers [29–
32]. On the other hand, it was reported that some microRNA such
as microRNA-29 family was transcriptional suppressed by c-Myc,
hedgehog and NF-kappaB [33]. Based on the evidence above, it is
possible that Hh-GLI might regulate DNMT3a through some
certain microRNAs, which remains to be explored.
In our study, ChIP assays showed GLI1 bind to DNMT1 but
not DNMT3a. We also noticed that GLI1 elevated DNMT3a
more folds than DNMT1. We thought there were some possible
underlying mechanisms as follows: First, GLI1 might not regulate
DNMT3a directly but through a certain gene, which might be a
kinaseoractivin,and via cascade amplification soasto lead a higher
regulativeefficiencyofDNMT3abyGLI1.Second,Hedghog-GLI1
might directly or indirectly regulate several genes involved in
different signaling pathways, and two or more of these genes also
regulate DNMT3a and have synergetic effects, so that despite GLI1
might not regulate DNMT3a directly, but would elevate DNMT3a
more folds when it over-expresses. To solve this question, it’s
necessary to explore more target genes of Hedgehog-GLI1, and to
probe into the crosstalk between various signaling pathways. We
thought the regulative relationship between Hh-GLI1 and DNMTs
would be not so simple as we already confirmed. Further studies are
also needed to explore whether the biological behavior of GLI1 in
PC may be achieved by regulating DNMTs.
The newly identified GLI1/DNMTs axis set a bridge between
Hh signaling pathway and epigenetics, which would help to
elucidate the underling molecular mechanism in the development
of PC, and may provide new therapeutic targets or biomarkers for
earlier diagnosis.
Supporting Information
Figure S1 Identificaton of positive clone products in
overexpression-GLI1 lentiviral vector construction. The
GLI1 cDNA products were inserted into linearized pGC-
FU-3FLAG vector to construct pGC-FU-GLI1 plasmid after
amplified and purified, then transformed into Competent Cells .
Transformants were identified with PCR and electrophoresed on
1.5% agarose gel, transformants-1 and -4 were showed as a 731 bp
band which proved to be positive clone.
(TIF)
Figure S2 Identification of GLI1 expression in pGC-FU-
GLI1 clone by WB. pGC-FU-GLI1 is constructed as a lentivirus
vector expressed GLI1, which was co-expressed with FLAG. (1)
WB molecular Weight Marker, with 3-FLAG label, fused with
GFP gene(48 KDa). (5–8) Sample after pGC-FU-GLI1 transfected
293T cells. (7) GLI1-FLAG fusion protein (122 KDa+2K -
Da=124 KDa), certificated GLI1 expression in pGC-FU-GLI1
plasmid.
(TIF)
Figure S3 Sequence analysis of positive clone products
in GLI1-overexpression lentiviral vector construction.
The resultant 3320-bp fragment was confirmed by sequencing
which is the same with the sequence of the GLI1 gene expression
region in GenBank (NM_005269.2).
(TIF)
Figure S4 Electropheretogram of sonicated chromatin
solution. Sonicated chromatin solution in different conditions
(100 W, 80 W and 60 W, respectively) were electrophoresed on
1.5% agarose gel containing ethidium bromied.
(TIF)
Figure S5 Sequence analysis of ChIP products which
amplified by DNMT1 primer-C. The result showed that the
sequence amplified with DNMT1 primer-C is the same as that of
DNMT1 gene promoter region containing GLI1-binding site 2
and 3.
(TIF)
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